L. David Sibley

This study identifies diffuse centromere organization in Cryptosporidium parvum, distinct from regional centromeres in related apicomplexans, suggesting an independent evolutionary origin.

The paper develops a Minimum Inoculum for Resistance (MIR) assay to evaluate anti-Toxoplasma gondii compounds, showing that inhibitors of phenylalanine tRNA synthetase require higher parasite inocula to induce resistance compared to DNA synthesis inhibitors.

This study investigates the role of alternative oxidase (AOX) and type II NADH dehydrogenase (NDH2) in generating the mitosome membrane potential in Cryptosporidium parvum, finding both genes are non-essential and not the target of known inhibitors.

This study shows that early-life Cryptosporidium parvum infection in mice disrupts oral tolerance by altering regulatory T cell development and inducing TH1 immune responses to dietary antigens.

The paper identifies 44 compounds with >50% inhibitory effects against Toxoplasma gondii bradyzoites using a high-throughput screen and characterizes one compound's activity.

This paper identifies a Toxoplasma gondii isolate that constitutively expresses bradyzoite regulators and readily differentiates into mature bradyzoites under stress, providing a new in vitro model for studying chronic infection.

This paper describes new bicyclic pyrrolidine inhibitors of Toxoplasma gondii PheRS with improved potency, selectivity, and brain exposure compared to previous azetidine-based inhibitors.

The paper investigates the role of GP60 in Cryptosporidium parvum infectivity, finding that while GP60 is not essential, its cleavage products affect parasite growth and infection severity.

This study investigates meiotic processes in Cryptosporidium parvum by analyzing chromosome segregation and recombination rates using transgenic parasites and in vitro cultures, revealing Mendelian inheritance and high crossover rates.